CHARM Therapeutics
LONDON, X0 · Biotechnology, Healthcare, Health Care · 35 employees
CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.
Funding history
- Funding Round — $17.3M — Sep 2025
- Series series b — $80.0M — Sep 2025
- Funding Round — $20.0M — Apr 2023
- Funding Round — $37.0M — Jun 2022
- Funding Round — $12.6M — Oct 2021
Recent signals
- Sep 03, 2025: Raised $17.3M
- Sep 02, 2025: Raised $80.0M in Series series b
- Sep 10, 2024: CHARM Therapeutics Appoints Dr Beverley Carr as Chief Business Officer
- Apr 30, 2024: CHARM Therapeutics Appoints Dr. Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development
- Apr 14, 2023: Raised $20.0M
- Jun 24, 2022: Raised $37.0M
- Oct 22, 2021: Raised $12.6M
See plans & pricing → Track CHARM Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.